4-Substituted D-glutamic acid analogues:: The first potent inhibitors of glutamate racemase (MurI) enzyme with antibacterial activity

被引:58
作者
de Dios, A
Prieto, L
Martín, JA
Rubio, A
Ezquerra, J
Tebbe, M
de Uralde, BL
Martín, J
Sánchez, A
LeTourneau, DL
McGee, JE
Boylan, C
Parr, TR
Smith, MC
机构
[1] Lilly SA, Eli Lilly & Co, Madrid 28108, Spain
[2] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] Univ Alcala de Henares, Dept Quim Organ, Madrid 28871, Spain
关键词
D O I
10.1021/jm020901d
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The first potent inhibitors of glutamate racemase (MurI) enzyme that show whole cell antibacterial activity are described. Optically pure 4-substituted D-glutamic acid analogues with (2R,4S) stereochemistry and bearing aryl-, heteroaryl-, cinnamyl-, or biaryl-methyl substituents represent a novel class of glutamate racemase inhibitors. Exploration of the D-Glu core led to the identification of lead compounds (-)-8 and 10. 2-Naphthylmethyl derivative 10 was found to be a potent competitive inhibitor of glutamate racemase activity (K-i = 16 nM, circular dichroism assay; IC50 = 0.1 mug/mL high-performance liquid chromatography (HPLC) assay). Thorough structure-activity relationship (SAR) studies led to benzothienyl derivatives such as 69 and 74 with increased potency (IC50 = 0.036 and 0.01 mug/mL, respectively, HPLC assay). These compounds showed potent whole cell antibacterial activity against S. pneumoniae PN-R6, and good correlation with the enzyme assay. Compounds 69, 74 and biaryl derivative 52 showed efficacy in an in vivo murine thigh infection model against Streptococcus pneumoniae. Data described herein suggest that glutamate racemase may be a viable target for developing new antibacterial agents.
引用
收藏
页码:4559 / 4570
页数:12
相关论文
共 38 条
[1]  
BALTZ RH, 1999, Patent No. 5981281
[2]   Vancomycin, teicoplanin, and ramoplanin: Synthetic and mechanistic studies [J].
Boger, DL .
MEDICINAL RESEARCH REVIEWS, 2001, 21 (05) :356-381
[3]  
BRYSON TA, 1980, J ORG CHEM, V45, P524, DOI 10.1021/jo01291a032
[4]   New directions in antibacterial research [J].
Chu, DTW ;
Plattner, JJ ;
Katz, L .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) :3853-3874
[5]   STEREOSELECTIVE ADDITION OF GRIGNARD-DERIVED ORGANOCOPPER REAGENTS TO N-ACYLIMINIUM IONS - SYNTHESIS OF ENANTIOPURE 5-SUBSTITUTED AND 4,5-SUBSTITUTED PROLINATES [J].
COLLADO, I ;
EZQUERRA, J ;
PEDREGAL, C .
JOURNAL OF ORGANIC CHEMISTRY, 1995, 60 (16) :5011-5015
[6]  
COLLADO I, 1994, TETRAHEDRON LETT, V35, P8037
[7]   PHARMACODYNAMICS OF AMIKACIN INVITRO AND IN MOUSE THIGH AND LUNG INFECTIONS [J].
CRAIG, WA ;
REDINGTON, J ;
EBERT, SC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :29-40
[8]   INACTIVATION OF ANTIBIOTICS AND THE DISSEMINATION OF RESISTANCE GENES [J].
DAVIES, J .
SCIENCE, 1994, 264 (5157) :375-382
[9]   Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States [J].
Doern, GV .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S187-S192
[10]   Solid-phase synthesis of substituted glutamic acid derivatives via Michael addition reactions [J].
Domínguez, E ;
O'Donnell, MJ ;
Scott, WL .
TETRAHEDRON LETTERS, 1998, 39 (15) :2167-2170